UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 2.471

Sortiert nach

Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

Annals of the rheumatic diseases, 2009-06, Vol.68 (6), p.789-796

2009

Volltextzugriff (PDF)

Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab

Annals of the rheumatic diseases, 2008-04, Vol.67 (4), p.511-517

2008

Volltextzugriff (PDF)

Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis

Annals of the rheumatic diseases, 2009-02, Vol.68 (2), p.175-182

2009

Volltextzugriff (PDF)

Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis-a prospective longitudinal study

Rheumatology (Oxford, England), 2011-11, Vol.50 (11), p.2061-2070

2011

Volltextzugriff (PDF)

Accidental hypothermia cardiac arrest treated successfully with invasive body cavity lavage

QJM : An International Journal of Medicine, 2018-08, Vol.111 (8), p.563-564

2018

Volltextzugriff (PDF)

Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension

Annals of the rheumatic diseases, 2010-04, Vol.69 (4), p.718-722

2010

Volltextzugriff (PDF)

Anti-TNF antibodies: lessons from the past, roadmap for the future

Handbook of experimental pharmacology, 2008 (181), p.101

2008

Volltextzugriff (PDF)

FRI0231 Treatment with BI 655064 (Antagonistic Anti-CD40 Antibody) Modulates Biomarkers Associated with Rheumatoid Arthritis (RA)

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.517

2016

Volltextzugriff (PDF)

Interaction studies on catecholamines to cellular receptors using in silico approach

Artery research, 2017-09, Vol.19 (1), p.29-37

2017

Volltextzugriff (PDF)

SAT0147 Safety and Efficacy of BI 655064, An Antagonistic Anti-CD40 Antibody in Rheumatoid Arthritis (RA) Patients

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.718

2016

Volltextzugriff (PDF)

479 Distinct patterns of gene expression in skin biopsies differentiate generalized pustular psoriasis (GPP) from psoriasis vulgaris (PV)

Journal of investigative dermatology, 2022-08, Vol.142 (8), p.S81

2022

Volltextzugriff (PDF)

272 An exome wide association study identifies new genetic determinants for palmar plantar pustulosis

Journal of investigative dermatology, 2022-12, Vol.142 (12), p.S227-S227

2022

Volltextzugriff (PDF)

Identification of Anti-Thrombin Antibodies in the Antiphospholipid Syndrome That Interfere with the Inactivation of Thrombin by Antithrombin

The Journal of immunology (1950), 2001-12, Vol.167 (12), p.7192-7198

2001

Volltextzugriff (PDF)

A Celebration of Difference: Science and Democracy in India

Science (American Association for the Advancement of Science), 1998-04, Vol.280 (5360), p.42-43

Visvanathan, Shiv

1998

Volltextzugriff (PDF)

LB946 Spesolimab controls chronic inflammation in GPP

Journal of investigative dermatology, 2024-08, Vol.144 (8), p.S165-S165

2024

Volltextzugriff (PDF)

094 Characterisation of the immunogenicity of spesolimab in patients with a generalized pustular psoriasis (GPP) flare

Journal of investigative dermatology, 2022-12, Vol.142 (12), p.S196-S196

2022

Volltextzugriff (PDF)

Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial

Annals of internal medicine, 2007-05, Vol.146 (9), p.621

2007

Volltextzugriff (PDF)

LB1140 Treatment with BI 655130, an anti-interleukin-36 receptor antibody, in patients with generalized pustular psoriasis, is associated with the downregulation of biomarkers linked to innate, Th1/Th17, and neutrophilic pathways

Journal of investigative dermatology, 2019-09, Vol.139 (9), p.B25-B25

2019

Volltextzugriff (PDF)

281 CARD14 variants are associated with palmar plantar pustulosis

Journal of investigative dermatology, 2019-09, Vol.139 (9), p.S263-S263

2019

Volltextzugriff (PDF)

388 Treatment with spesolimab, an anti-interleukin-36 receptor antibody, in patients with generalized pustular psoriasis, is associated with the downregulation of biomarkers linked to innate, Th1/17 and neutrophilic pathways

Journal of investigative dermatology, 2019-09, Vol.139 (9), p.S281-S281

2019

Volltextzugriff (PDF)

049 Generalized pustular psoriasis (GPP) and palmoplantar pustulosis (PPP) both show upregulation of the IL-36, neutrophil chemokine, and innate pathways that are modulated by spesolimab, an anti-IL-36 receptor antibody, treatment

Journal of investigative dermatology, 2020-07, Vol.140 (7), p.S5-S5

2020

Volltextzugriff (PDF)

119 RELATIONSHIPS AMONG AND DISCRIMINATORY ABILITY OF INFLAMMATORY MEDIATORS IN SERUM AND SYNOVIAL FLUID IN A CROSS-SECTIONAL OSTEOARTHRITIS COHORT

Osteoarthritis and cartilage, 2007, Vol.15, p.C75-C75

2007

Volltextzugriff (PDF)

103 MEASUREMENT AND CORRELATION OF INFLAMMATORY MEDIATORS IN SERUM AND SYNOVIAL FLUID FROM A CROSS-SECTIONAL OSTEOARTHRITIS COHORT

Osteoarthritis and cartilage, 2007, Vol.15, p.C66-C66

2007

Volltextzugriff (PDF)

Marine Plastics Abatement: Technology, Management, Business and Future Trends (Volume 2)

2023

Volltextzugriff (PDF)

Marine Plastics Abatement: Challenges, Implications, Assessments and Circularity (Volume 1)

2023

Volltextzugriff (PDF)

1 – 25 von 2.471

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.017)
Mit Volltextzugriff
(2.208)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)
... seit 90 Tagen
(23)

Menü

Weitere Dienste

Einstellungen

Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab

Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis

Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis-a prospective longitudinal study

Accidental hypothermia cardiac arrest treated successfully with invasive body cavity lavage

Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension

Anti-TNF antibodies: lessons from the past, roadmap for the future

FRI0231 Treatment with BI 655064 (Antagonistic Anti-CD40 Antibody) Modulates Biomarkers Associated with Rheumatoid Arthritis (RA)

Interaction studies on catecholamines to cellular receptors using in silico approach

SAT0147 Safety and Efficacy of BI 655064, An Antagonistic Anti-CD40 Antibody in Rheumatoid Arthritis (RA) Patients

479 Distinct patterns of gene expression in skin biopsies differentiate generalized pustular psoriasis (GPP) from psoriasis vulgaris (PV)

272 An exome wide association study identifies new genetic determinants for palmar plantar pustulosis

Identification of Anti-Thrombin Antibodies in the Antiphospholipid Syndrome That Interfere with the Inactivation of Thrombin by Antithrombin

A Celebration of Difference: Science and Democracy in India

LB946 Spesolimab controls chronic inflammation in GPP

094 Characterisation of the immunogenicity of spesolimab in patients with a generalized pustular psoriasis (GPP) flare

Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial

LB1140 Treatment with BI 655130, an anti-interleukin-36 receptor antibody, in patients with generalized pustular psoriasis, is associated with the downregulation of biomarkers linked to innate, Th1/Th17, and neutrophilic pathways

281 CARD14 variants are associated with palmar plantar pustulosis

388 Treatment with spesolimab, an anti-interleukin-36 receptor antibody, in patients with generalized pustular psoriasis, is associated with the downregulation of biomarkers linked to innate, Th1/17 and neutrophilic pathways

049 Generalized pustular psoriasis (GPP) and palmoplantar pustulosis (PPP) both show upregulation of the IL-36, neutrophil chemokine, and innate pathways that are modulated by spesolimab, an anti-IL-36 receptor antibody, treatment

119 RELATIONSHIPS AMONG AND DISCRIMINATORY ABILITY OF INFLAMMATORY MEDIATORS IN SERUM AND SYNOVIAL FLUID IN A CROSS-SECTIONAL OSTEOARTHRITIS COHORT

103 MEASUREMENT AND CORRELATION OF INFLAMMATORY MEDIATORS IN SERUM AND SYNOVIAL FLUID FROM A CROSS-SECTIONAL OSTEOARTHRITIS COHORT

Marine Plastics Abatement: Technology, Management, Business and Future Trends (Volume 2)

Marine Plastics Abatement: Challenges, Implications, Assessments and Circularity (Volume 1)

Suchergebnisse filtern